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Background: The Arctic mutation (p.E693G/p.E22G)fs within the β-amyloid (Aβ) region of the β-amyloid precursor
protein gene causes an autosomal dominant disease with clinical picture of typical Alzheimer’s disease. Here we
report the special character of Arctic AD neuropathology in four deceased patients.
Results: Aβ deposition in the brains was wide-spread (Thal phase 5) and profuse. Virtually all parenchymal deposits
were composed of non-fibrillar, Congo red negative Aβ aggregates. Congo red only stained angiopathic vessels.
Mass spectrometric analyses showed that Aβ deposits contained variably truncated and modified wild type and
mutated Aβ species. In three of four Arctic AD brains, most cerebral cortical plaques appeared targetoid with
centres containing C-terminally (beyond aa 40) and variably N-terminally truncated Aβ surrounded by coronas
immunopositive for Aβx-42. In the fourth patient plaque centres contained almost no Aβ making the plaques
ring-shaped. The architectural pattern of plaques also varied between different anatomic regions. Tau pathology
corresponded to Braak stage VI, and appeared mainly as delicate neuropil threads (NT) enriched within Aβ plaques.
Dystrophic neurites were scarce, while neurofibrillary tangles were relatively common. Neuronal perikarya within the
Aβ plaques appeared relatively intact.
Conclusions: In Arctic AD brain differentially truncated abundant Aβ is deposited in plaques of variable numbers
and shapes in different regions of the brain (including exceptional targetoid plaques in neocortex). The extracellular
non-fibrillar Aβ does not seem to cause overt damage to adjacent neurons or to induce formation of neurofibrillary
tangles, supporting the view that intracellular Aβ oligomers are more neurotoxic than extracellular Aβ deposits.
However, the enrichment of NTs within plaques suggests some degree of intra-plaque axonal damage including
accumulation of hp-tau, which may impair axoplasmic transport, and thereby contribute to synaptic loss. Finally,
similarly as the cotton wool plaques in AD resulting from exon 9 deletion in the presenilin-1 gene, the Arctic plaques
induced only modest glial and inflammatory tissue reaction.
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Deposition of amyloid-β (Aβ) peptides and hyperphos-
phorylated tau (hp-tau) as neurofibrillary tangles (NFT),
dystrophic neurites (DN) and neuropil threads (NT) are
invariably found in the brains of patients with both spor-
adic and familial forms of Alzheimer’s disease (AD). The
majority of the pathogenic mutations in the amyloid-β
precursor protein (AβPP) gene (http://www.alzforum.org/
res/com/mut/app/default.asp) results in either an increase
in total Aβ or Aβ42/Aβ40-ratio and often in aggressive
plaque pathology. The recently reported protective effect
against AD of the p.A673T substitution in AβPP (p.Α2Τ in
Aβ peptide) further suggests that Aβ is pivotal for the dis-
ease development [1].
Distinct pathological features are seen in AβPP muta-
tion carriers as well as in other early-onset familial forms
of AD. For example, brains from carriers of mutations in
exons 8 and 9 of the presenilin 1 gene (e.g. PS1Δ9) harbour
cotton wool plaques; large ball-like plaques without an
amyloid core [2-4].
Similarly, there is a marked phenotypic variation also
among patients with various AβPP mutations [5], which is
exemplified by different substitutions in AβPP codon 693.
For example, both the Dutch AβPP mutation (p.E693Q;
reviewed in [6]) and the Italian mutation (p.E693K; [7,8])
within the Aβ sequence cause amyloid angiopathy with in-
tracerebral hemorrhages, whereas parenchymal AD path-
ology and dementia are subsidiary. Moreover, the Osaka
AβPP deletion mutation (p.E693Δ) identified in a Japanese
pedigree also causes a primarily dementing disease [9]. The
Arctic AβPP mutation (p.E693G; in Aβ-peptide p.E22G)
was initially reported as a polymorphism of unclear patho-
genic significance [10]. Subsequently, the same mutation
was found to segregate with AD in a Swedish family [11].
Interestingly, the Arctic AβPP mutation increased the
formation of large soluble Aβ oligomers/protofibrils
[11,12], while symptomatic carriers showed low CSF-
Aβ42 levels but remained PIB-PET negative [13]. The
Osaka AβPP deletion mutation (p.E693Δ) also acceler-
ated Aβ oligomerization [9] but it did not cause depos-
ition of fibrillar Aβ in vivo, neither in transgenic mice nor
in AD patients [9,14].
Elevated intra- or extracellular levels of Aβ oligomers/
protofibrils are believed to be of pathogenic significance
and neurotoxic effects have been demonstrated both on
cultured cells and in vivo. For example, intrathecal ad-
ministration of Aβ oligomers in rats caused impaired
learning [15] and extracellular accumulation of soluble
dodecameric Aβ in the brains of AβPP transgenic mice
impaired cognition independently of plaques or neuronal
loss [16].
We have previously reported epidemiological and clin-
ical as well as a limited description (based on two Arctic
AD brains) of some neuropathological features resultingfrom the p.E693G mutation in AβPP [17]. Apart from
concluding that the clinical features of this mutation are
compatible with AD, we identified ring-formed Aβ plaques
but did not further study the overall neuropathology.
In another, more recent, biochemically oriented study
[18] we analysed the composition of Arctic Aβ plaques
in the frontal and temporal cortex of two Arctic AD pa-
tients (patients Sw1 and Sw2 of this study) using bio-
chemistry (including Aβ ELISA and MALDI-TOF and
MALDI-imaging mass spectrometry) and complementary
immunohistochemistry and electron microscopy. Aβ ELISA
and mass spectrometry analyses on brain cortex samples
from one of our patients (patient Sw2 of this study) with
the Arctic AβPP mutation revealed deposition of a het-
erogeneous mixture of Aβ peptides with a significant
contribution of N-truncated and N-terminally modified Aβ.
Moreover, by applying mid-domain, N- and C-terminal
specific Aβ antibodies we demonstrated in the temporal
cortex (patient Sw2 of this study), the presence of targetoid
plaques composed of both N- and C-terminally truncated
Aβ [18].
Here, we have extended and made a comprehensive
analyses of the neuropathology in Arctic AβPP mutation
carriers, based on four autopsied brains. We have applied
nine well-characterized antibodies to different epitopes
spanning the Aβ molecule, including an antibody spe-
cific to the Arctic mutation p.E22G and two antibodies
recognizing posttranslational modifications of glutamates 3
and 11 of Aβ (cyclization into pyroglutamate). Thus, we
could define the pattern of differentially truncated and
N-terminally modified Aβ deposition in different regions
of the Arctic AD brains, and also correlate these to mass
spectroscopic findings in cerebral cortex. In addition, we
describe local effects of Aβ on neurons, the association
of Aβ with other pathological features, such as accumula-
tion of hp-tau, macro- and microglial reactions, and basic
vascular alterations.
Methods
Patients and brain specimens
Two patients from a Swedish and two from an American
family were included in the study. The presence of the
Arctic mutation was verified by sequencing of exon 17
of the AβPP gene according to the methods previously
described [11]. Although not proven, these two families
are believed to descend from the same Swedish ancestor,
(for respective pedigrees, see Figure 1a-b). The Swedish
patients died at 62 (Sw1 = IV:10) and 64 (Sw2 = IV:29)
years of age, after six and eight years of disease duration,
respectively. The American patients died at 72 (Am1 =
III:1) and 59 (Am2 = IV:1) years of age after 16 and 8 years
of disease duration, respectively.
This study has been carried out in compliance with
the Helsinki Declaration and it has been approved by
Figure 1 Pedigrees of the Arctic AD families (a and b) and basic pathology in Sw2 patient (c-e). a and b: Pedigrees of the Swedish and
American families with the Arctic AβPP gene mutation. Diagonal lines indicate deceased individuals; filled symbols indicate affected and open
symbols unaffected members. The patients examined in this study in Family a are: IV:10 = Sw1, IV:29 = Sw2 and in Family b: III:1 = Am1, IV:1 = Am2.
c: Sw2 patient’s brain weighed 1490 g. The gyri are only mildly atrophic, whereas the atrophy of hippocampus (arrow) and the dilatation of the
ventricular system (asterisks) are obvious. d and e: Semi-consecutive sections from Sw2 patient’s frontal cortex: d: The plaques (five marked with an
arrow) are discernible already with H&E staining. They are rounded, compact, eosinophilic structures with homogeneous texture, reminiscent of so
called cotton wool plaques [3]. Inset in d: Both pial and penetrating arteries are strongly Congo positive, but no plaques are visible. e: In a
Bielschowsky silver impregnated section several plaques are vaguely ring formed (four marked with an arrow). No prominent dystrophic neurites
are seen, only short, thin stubs. Inset (the square in e): Occasional plaques harbour somewhat coarser dystrophic neurites (arrow). Open arrow
points to a neuron with neurofibrillary tangle. (bar in d 100 μm for d and e; bar in inset of e 40 μm).
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089; 2009-04-22 and 2005-103; 2005-2006-29.
The brains were routinely fixed in buffered 4% formal-
dehyde, within twelve hours post mortem and widely
sampled for embedding in paraffin. For comparison we
used brain samples from five AD patients with the cotton
wool plaque-associated PS1Δ9 mutation [3].
Histopathology and immunohistochemistry
The basic histopathology was examined in sections stained
with hematoxylin and eosin (H&E), Bielschowsky’s silver
impregnation, thioflavin-S, Congo red or periodic acid
Schiff (PAS) stains. The antibodies used for immunohisto-
chemistry of Aβ hp-tau, astrocytes, microglia and neurons
are listed in Table 1. Well characterized antibodies to dif-
ferent epitopes in wild type (wt) Aβ, called general Aβ-
antibodies (Table 1), were selected to identify epitopes in
N-terminal, mid-domain and C-terminal regions of non-
mutated Aβ. Among those none is selective for wild-type
Aβ and only antibody abAβ17-24 (clone 4G8) has reducedaffinity for Arctic Aβ. In addition, specific antibodies recog-
nizing Aβ with the Arctic mutation and certain post-
translational truncations and modifications, were applied
(Table 1).
After pre-treatment relevant for each antigen, the sec-
tions were incubated with the primary antibodies overnight
at +4°C, followed by incubation with relevant second-
ary antibodies and visualization using the avidin-biotin-
peroxidase method with diaminobenzidine as chromogen
(Vectastain, Vector Laboratories, Burlingame, CA, USA).
Neurons and their axons were double-labelled with a poly-
clonal Aβx-40 antibody and a monoclonal antibody to
neurofilament, followed by Alexa 633 labeled anti-rabbit
and Alexa 488 labeled anti-mouse secondary antibodies
(Molecular Probes, Eugene, OR, USA). The details of anti-
body sources and specifications are listed in the Table 1.
Mass spectroscopy
For comparative immunohistochemical and mass spec-
troscopic analyses of Aβ in cortical plaques, samples of
Table 1 The list of antibodies used in immunohistochemistry and immunoprecipitation experiments
Antibody Epitope/Target Manufacturer
N-terminal Aβ-antibodies
mAb 82E1 Neoepitope Aβ1-5 IBL, Hamburg, Germany
mAb 6E10 Aβ5-10 Covance, Berkeley, CA, USA
Mid-domain Aβ-antibodies
mAb 6F/3D Aβ8-17 Novocastra, Newcastle, U.K.
mAb 4G8 Aβ17-24 Covance
C-terminal Aβ-antibodies
rpAb 40 Aβx-40, neoepitope Biosource/Invitrogen, Camarillo CA, USA
rpAb 42 Aβx-42, neoepitope Biosource/Invitrogen
Special Aβ-antibodies
mAb 27 Aβ20-24 with Arc-mutation p.E22G Lord et al. 2009 [19]
mAb 2-48 Aβ3pE Synaptic Systems, Göttingen, Germany
rpAb 11pE Aβ11pE Synaptic Systems
Antibodies to cellular alterations
mAb AT8 Hyperphosphorylated tau Innogenetics, Zwijndrecht, Belgium
mAb GFAP Glial fibrillary acidic protein Dako, Glostrup, Denmark
mAb HLA-DP, DQ, DR Microglial cells Dako
rpAb Iba1 Microglial cells Wako, Osaka, Japan
rpAbα1-antitrypsin Lysosomes Dako
rpAb cathepsin D Lysosomes Dako (production discontinued)
Abbreviations: mAb mouse monoclonal antibody, rpAb rabbit polyclonal antibody.
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munoprecipitated (with antibodies to Aβ17–24 and
Aβarc) and analysed by MALDI-TOF, as described in
our previous study [18].Results
Macroscopic pathology
Patient Sw1 (IV:10): ApoE genotype 3/3. The brain weighed
1385 g. Gross examination revealed focal moderate atrophy
of parietal superior lobules. There were no signs of infarcts
or hemorrhages.
Patient Sw2 (IV:29): ApoE genotype 3/3. The brain
weighed 1490 g. A mild degree of atrophy with dilatation
of the ventricular system was seen in frontal, parietal and
occipital lobes as well as in different parts of the temporal
lobe, including gyrus parahippocampalis, hippocampus,
and amygdala (Figure 1c). Brainstem and cerebellum had
normal macroscopic appearance, apart from mild atrophy
of the anterior part of vermis.
Patient Am1 (III:1): ApoE genotype 2/3. The weight of
the brain was 822 g. There was a severe degree of atro-
phy in frontal, temporal and parietal cortices [17].
Patient Am2 (IV:1): ApoE genotype 2/3. After fixation,
the brain weighed 1220 g and showed moderate cortical
atrophy.Microscopic pathology of Aβ deposition
The deposition of Aβ in human brain has been sug-
gested to follow a distinct hierarchical sequence, clas-
sified as phases 1 to 5 [20]. In the following, we present
the structural and immunohistochemical findings in the
anatomical regions corresponding to these phases. The
pattern of Aβ deposits varied both with respect to the
antibodies applied and to the different brain regions
analysed. Furthermore, there were some noticeable differ-
ences between the four Arctic AD brains studied.Cerebral neocortices (phase 1)
Histopathology
In H&E stained sections, senile plaques appeared as
compact rounded structures with remarkably homo-
genous texture (Figure 1d). The plaques were devoid
of an amyloid core, as shown by the absence of Congo
red (Figure 1d, inset) and thioflavin S (not shown)
positivity and thus resembled cotton wool plaques
(Additional file 1: Figure S9) [2,3]. With Bielschowsky
silver impregnation (without gold enhancement) the
plaques were moderately brownish with accentuation
of peripheral parts and negative or weakly stained cen-
tres, giving the plaques a vaguely ring-like pattern
(Figure 1e).
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General features
The area fraction of Aβ immunopositivity (Aβx-42) in
frontal, temporal and parietal cortices was about 25%.
Plaques were present in all cortical layers, being most nu-
merous and compact in layers 2 and 3, while in deeper
layers they were somewhat larger and less distinct. In
addition, in layer 1 there were often small diffuse plaques
of variable numbers, shapes and staining intensities, as
well as thin patchy variably immunopositive subpial
bands (Figure 2a-h). The variation in the cortical pattern
appeared e.g. in occipital cortex, where layers 4 and 6
were virtually devoid of plaques and layer 5 displayed
only a lesser number of diffuse plaques (Figure 2d and
Additional file 2: Figure S7c). Variation between patients
was also observed e.g. as a paucity of plaques in layer 4 in
frontal cortex of patients Am1 and Am2 compared to
more abundant plaques in the same region in patients
Sw1 and Sw2 (Additional file 3: Figure S1a-g, Additional
file 4: Figure S2a, and Figure 2a).Figure 2 Aβ immunostainings of Sw2 patient’s frontal cortex. a: The p
and 3. b and c: Higher magnifications of the region within the rectangle. b
homogeneously. c: In a consecutive section abAβx-42 leaves the centres pa
the plaques are sharply delineated like the so-called cotton wool plaques (
deposits (arrowhead) and thin subpial patches (open arrow) in layer 1. d: In
cortical layers is prominent. Note the abundant vascular Aβ deposition in m
deep in layer 4. (See also Additional file 2: Figure S7c). e-h: Sections from th
comprehensive staining of plaques. f-h: The more N-terminal antibodies hi
for b-c and e-h).Staining with general Aβ antibodies
With the C-terminal abAβx-42 a majority of neocortical
plaques in all four patients were ring-shaped (Figure 2c),
as described in the first study on patient Sw1 [17], i.e. the
weakly stained centres of larger plaques were surrounded
by distinct immunoreactive coronas.
In patient Sw1 the ring pattern visualized with abAβx-42
[11] was also clearly noticeable with abAβx-40, abAβ8–17,
abAβ5–10, and abAβarc. The staining was progressively
weaker and less distinct with the more N-terminal abs
(Additional file 4: Figure S2a-g) and nearly negative with
abAβ1–5, although with this antibody the small subpial
plaques were still positive (Additional file 4: Figure S2f).
No central accentuation with the N-terminal antibodies
was observed (Additional file 4: Figure S2e-f).
In patients Sw2 and Am 1, on the contrary, the neo-
cortical plaques displayed a targetoid pattern: In these
two brains the plaques were ring-shaped only with the
most C-terminal antibody abAβx-42 (Figure 2c), whereas
with abAβx-40 the centre was clearly immunopositivelaques in frontal cortex are most numerous and compact in layers 2
: Antibody Aβx-40 stains the plaques, including their centres, relatively
le disclosing the targetoid pattern of many plaques (arrows). In general
cf. Figure 7b and Additional file 1: Figure S9). Note the small diffuse Aβ
occipital cortex (striate area) the variable deposition of Aβ in different
eningeal and penetrating parenchymal arteries as well as in capillaries
e same region as in a-c. e: Mid-domain abAβ17–24 gives the most
ghlight plaque centres. (bar in a 500 μm for a and d; bar in b 200 μm
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plaques most compact of all antibodies (Figure 2e),
whereas antibodies with epitopes towards the N-terminus
stained the plaque coronas more weakly and centres more
intensely (Figure 2f-h, Additional file 3: Figure S1d-f). Con-
focal analysis of sections from patient Sw2 double immu-
nostained with abAβx-42 and abAβ1-5 clearly distinguished
the two Aβ components in plaques: the peripheral corona
was positive with abAβx-42, while the centre was stronglyFigure 3 Aβ immunostainings of Sw2 patient’s frontal and temporal c
cortex. a: Confocal micrograph from Sw2 patient’s temporal cortex shows
the centre Aβ1-5 species. b: The central accentuation of abAβarc (specific fo
mutated Aβ has preserved N-termini (Sw2, frontal cortex; see Figure 2g and
demonstrate that much of the Aβ is truncated and glutamates 3 and 11 ar
at both sites. Note the strong positivity in pial arteries (Sw2, temporal corte
extracted from Sw2 patient’s temporal cortex with formic acid and immun
epitope 17-24arc), which precipitate both wild type Aβ and Arctic Aβ (s
(with the Arctic mutation) and recognized by AβpE specific antibodies (value
and m/z=3062.8 Da→ Aβ11pE-40arc; m/z=3246.2 and m/z=3246.0 Da→ A
corresponding to arcAβ with full length N-termini (m/z=4258.7 and m/z= 42
labelled. Additional values with relative intensities of the peaks, see Additionpositive with abAβ1-5 (Figure 3a). Therefore, the plaques
could best be described as targetoid, not ring-shaped.
In patient Am2 the staining pattern was more variable.
In this patient’s frontal cortex it was similar as in patient
Sw1, i.e. the more N-terminal abs also rendered the
plaques ring shaped without intensely stained centres,
although the staining was less distinct and much weaker
(cf. Additional file 4: Figure S2). On the other hand, in
Am2 patient’s temporal and occipital cortex many plaquesortex and mass spectra of Aβ peptides in Sw2 patient’s temporal
the targetoid pattern of the plaque: the corona contains Aβx-42 and
r the Arctic mutation) immunopositivity suggests that much of the
h). c and d: Pyroglutamate specific abAβ3pE and abAβ11pE antibodies
e cyclised into pyroglutamate and this modification occurs in parallel
x, consecutive sections). e: Average mass spectra of Aβ peptides
oprecipitated with abAβ17–24 and abAβArc (conformation specific
ee inserted cartoon). Three peaks corresponding to arcAβ species
s observed in two independent MALDI-TOF experiments m/z=3061.5
β11pE-42arc; m/z=4057.0 Da→ Aβ3pE-40arc) as well as two peaks
59.1 Da→ 1-40arc; m/z=4443.5 and m/z=4443.0 Da→ 1-42arc) are
al file 5: Table S1. (bar in a 50 μm; bar in b 200 μm for b-d).
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in patients Sw2 and Am1 (cf. Figure 2 and Additional
file 3: Figure S1).
Staining with specific Aβ antibodies
In patient Sw1 almost all plaques were ring-shaped with
the Arctic specific antibody abAβarc (Additional file 4:
Figure S2g). In patients Sw2, Am1 and Am2 the staining
pattern with abAβarc resembled that with the mid-domain
abAβ17-24, although it was somewhat weaker (Figures 3b
vs. 2e and Additional file 3: Figure S1g vs. S1c).
In patients Sw2 and Am1 the antibodies abAβ3pE
and abAβ11pE showed that N-terminally truncated Aβ
starting with pyroglutamate (Aβ3pE and Aβ11pE) colocalized
in frontal cortical plaques, although the staining with
abAβ11pE was weaker than with abAβ3pE (for Sw2
Figure 3c-d and for Am 1 Additional file 3: Figure S1h-i).
Aβ3pE stained most plaques relatively homogeneously
and much more extensively than the other N-terminal
abAβ1–5 (cf. Figure 2h). Some strongly abAβ1–5 posi-
tive centres were also abAβ3pE positive (Additional file 3:
Figure S1h). Moreover, we observed vague predominant
deposition of Aβ11pE to the plaque centres (Figure 3d).
Correspondence between Aβ immunohistochemistry
and mass spectrometry
Analysis by MALDI-TOF of Aβ peptides immunopre-
cipitated from Sw2 patient’s temporal cortex resulted
in various peaks within the m/z range of 2000–5000
Da (Figure 3e and Additional file 5: Table S1). Note-
worthy, several of the Aβ species (see labels) corres-
ponded well with the predicted masses of AβpE species,
as detected by specific Aβ antibodies (abAβ3pE and
abAβ11pE; Figure 3c-d). The observed and predicted m/z
values with their relative intensities, corresponding to
the peaks shown in Figure 3e are presented in Additional
file 5: Table S1.
Allocortical brain regions (phase 2)
Histopathology
Plaques in hippocampus were not as easily discernible
with H&E staining as in neocortex–except for those lo-
cated in dentate gyrus, where they were found to displace
granular cells (Additional file 6: Figure S3a). In adjoining
occipito-temporal cortex the pattern was similar as else-
where in cerebral cortex. Although with Bielschowsky
silver impregnation, both DNs and NFTs were strongly
positive (Additional file 6: Figure S3b and inset), hippo-
campal plaques were virtually silver negative. However,
in the same sections plaques in the nearby occipito-
temporal cortex were clearly silver positive and the Aβ
immunostainings of hippocampal plaques were intensely
positive (see below). Congo red staining was negative
(not shown).Aβ immunohistochemistry
With Aβ immunostaining, the plaques were numerous
throughout hippocampus, but their frequency and pattern
varied in different hippocampal regions (Figure 4a-f).
In the CA1-CA4 sectors, the general Aβ antibodies
disclosed abundant Aβ deposits of variable size and ir-
regular shape. Remarkably, in hippocampus the plaques
did not show such a distinct targetoid pattern as in cere-
bral cortex. Instead, they were small with a diffuse pat-
tern when stained with different Aβ antibodies (insets of
Figure 4a-f ). In CA3 and CA4 sectors, in addition to the
better defined plaques there were also background-like
diffuse Aβ deposits, whereas in CA1 and CA2 such de-
posits were uncommon (Figure 4a-f ).
Using the C-terminal abAβx-42 (Figure 4a) and abAβx-40
(Figure 4b), as well as the mid-domain abAβ17–24
(Figure 4c), the staining was recognizably stronger and
the plaques were slightly more frequent than with the
N-terminal antibodies abAβ8–17, abAβ5–10 and abAβ1–5
(Figure 4b). Diffuse plaques were also abundant in stratum
radiatum, subiculum (Figure 4a-f ) and transentorhinal
cortex, whereas in entorhinal cortex they were rela-
tively sparse. In the adjoining occipito-temporal cortex
the plaques appeared similar as elsewhere in neocor-
tex (cf. Figure 2a-h and Additional file 3: Figure S1 and
Additional file 4: Figure S2).
Staining of allocortical sections with the specific Aβ
antibodies abAβarc (Figure 4e), abAβ3pE (Figure 4f ) and
abAβ11pE (not shown) gave similar patterns as the gen-
eral Aβ antibodies. The staining intensities were com-
parable to that of N-terminal abAβ1−5 (Figure 4d).
Subcortical grey matter nuclei (phase 3)
Histopathology
In basal nuclei, plaques were most often not discernible
with H&E or silver staining, but they were selectively
positive for Aβ with immunohistochemistry (see below).
In this region, the Congo red staining was negative in
the parenchyma.
Aβ immunohistochemistry
Among the basal nuclei, claustrum was remarkably deviant:
Aβ was deposited as large compact plaques, which had
similar targetoid staining pattern as plaques in neocortex
(Additional file 7: Figure S4a-g). On the contrary, in the
neighbouring putamen the plaques were small and diffusely
stained (Additional file 7: Figure S4h-k). These plaques
were positive with the C-terminal abAβx-42 (Additional
file 7: Figure S4h) and abAβx-40, as well as with mid-
domain abAβ17-24 (not shown) and were weakly positive
with abAβarc (Additional file 7: Figure S4j) and abAβ11pE
(not shown). With the N-terminal abAβ1-5 plaques were al-
most negative (Additional file 7: Figure S4i), whereas with
the pyroglutamate specific N-terminal abAβ3pE the plaques
Figure 4 Hippocampal region from patients Sw1 (a-e; consecutive sections) and Sw2 (f). The general pattern of Aβ deposits is fairly similar
with all antibodies, although the intensity of staining is somewhat stronger and the size of plaques larger with the C-terminal abAβx-42 (a) and
abAβx-40 (b), as well as with the mid-domain abAβ17-24 (c) than with the N-terminal abAβ1-5 (d) and the specific antibodies abAβarc (e) and
abAβ3pE (f).The insets from the CA4 regions within the squares demonstrate that the plaques are mostly of diffuse type. In addition, especially in
sectors CA3 and CA4, there is abundant, diffuse, lightly stained “background” deposition of Aβ. In stratum radiatum (sr) the plaques are somewhat
larger and more compact. Note: no targetoid plaques with abAβx-42 and abAβ1-5 (such as in cerebral cortex). (bar in a 1100 μm for all panels).
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In amygdala the Aβ deposition was similar to that in pu-
tamen, though with C-terminal antibodies the numberof small diffuse plaques was greater (Additional file 7:
Figure S4l). In thalamus (Additional file 7: Figure S4m)
and caudate nucleus (not shown) the plaques were ragged
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completely negative for Aβ-immunoreactivity (not shown).
Brain stem (midbrain, pons and medulla; phase 4)
Histopathology
In midbrain, pons and medulla, Aβ deposits were not
discernible with H&E and only weakly positive with sil-
ver staining. None of the parenchymal Aβ deposits were
positive for Congo red (not shown).
Aβ immunohistochemistry
In midbrain, the deposition of Aβ was scarce. Diffuse
weakly stained Aβ deposits were discernible almost exclu-
sively in nucleus ruber. Among the different Aβ antibodies,
only abAβx-42 and abAβ17–24 stained these plaques. How-
ever, amyloid angiopathy could be clearly visualized with
all Aβ antibodies (not shown). In pons, virtually no paren-
chymal deposits were observed despite brisk staining of
blood vessels (not shown). In medulla, a few distinct
plaques, strongly positive with all Aβ antibodies used were
present in inferior olivary (Additional file 8: Figure S5a-i)
and dorsal vagal nuclei (not shown). The pattern, num-
ber and size of plaques in medulla were approximately
similar with both general and specific Aβ antibodies, al-
though some variation in the intensity was observed
(Additional file 8: Figure S5d-i). Remarkably, abΑβx-42
rendered the neuropil in inferior olivary nucleus distinctly
positive (Additional file 8: Figure S5a and d), whereas with
all other Aβ antibodies it was negative (e.g. Additional
file 8: Figure S5b-c and e-i). Olivary neurons within
the plaques appeared fairly well preserved (Additional
file 8: Figure S5d-k), but both abΑβx-42 and abAβ17–24
stained cytoplasmic inclusions within inferior olivary
neurons (Additional file 8: Figure S5d-e), as did also
PAS and an antibody to lysosomal cathepsin D (Additional




In H&E stained sections the Aβ deposits were not de-
tectable (not shown). Bielschowsky silver showed no im-
pregnation in the Purkinje cell layer (see below) and
only a small number of weakly positive perivascular streaks
or smaller deposits in the molecular layer perpendicular to
the surface (not shown). As elsewhere, Congo red did not
reveal any parenchymal staining.
Aβ immunohistochemistry
The amount of Aβ deposited in cerebellum was much
more abundant than that normally seen in AD. Further-
more, the pattern of the deposits was remarkably different
from elsewhere in the Arctic AD patients’ brains, especially
compared to the cerebral cortices. The immunopositive Aβdeposits were highly variable in size and had very irregular
configurations, while distinct rounded Aβ plaques were
completely absent. Furthermore, there were marked inter-
individual differences, e.g. Aβ deposits in patient Am1 were
distinctly different from those in patients Sw1, Sw2 and
Am2 (see below).
In patients Sw1, Sw2 and Am2 with similar Aβ stain-
ing pattern, the C-terminal abAβx-42 (Figures 5a and 6b)
and abAβx-40 (Figure 5b) as well as the mid-domain
abAβ17–24 (Figure 5c) displayed diffuse patchy staining
in the Purkinje cell layer, from where irregular immuno-
reactive streaks extended across the molecular layer to-
wards the surface, often following the penetrating blood
vessels as wide and irregular cuffs (Figure 5a-c). A simi-
lar pattern, although with markedly weaker intensity,
was obtained with the pyroglutamate specific abAβ3pE
(Figure 5h) and abAβ11pE (Figure 5i). The staining was
still weaker with the other N-terminal antibodies abAβ8–17,
abAβ5–10 and abAβ1–5 (Figure 5d-f ), as well as with
abAβarc (Figure 5g). All Aβ antibodies used gave robust
staining of blood vessel walls (Figure 5a-i).
In Am1 patient the staining pattern with abAβx-42 and
abAβ17–24 (Additional file 9: Figure S6a and c) was al-
most similar as in the three brains described above,
whereas with the C-terminal abAβx-40 (Additional file 9:
Figure S6b) and mid-domain abAβ8-17 (Additional file 9:
Figure S6d) both the deposits in the granular/Purkinje
cell border zone and the streaks in the molecular layer
were scarce and weak, although blood vessels were clearly
positive. In this brain the more N-terminal abAβ8–17,
abAβ5–10 and abAβ1–5 (Additional file 9: Figure S6d-f)
stained almost exclusively arterial vessel walls. Among the
specific antibodies the staining with Aβarc was faint,
whereas both abAβ3pE and abAβ11pE gave clear staining
Additional file 9: Figure S6g-i).
Intracellular Aβ immunoreactivity
In all brains definite cytoplasmic immunoreactivity
was observed in inferior olivary neurons with abAβx-42
and abAβ17–24 (Additional file 8: Figure S5d-e). The
cytoplasmic Αβ(or AβPP [21]) immuno-positivity per-
sisted, even if the formic acid pretreatment was omitted,
whereas the extracellular Aβ deposits in the medulla
were immunonegative (not shown). These granular cyto-
plasmic inclusions in inferior olivary neurons were also
positive with PAS (Additional file 8: Figure S5j), cathep-
sin D (Additional file 8: Figure S5k), and α1-antitrypsin
(not shown).
Cytoplasmic immunoreactivity with abAβ17–24 was ob-
served also in some other locations, most prominently in
cerebellum, both in Purkinje cells (Figure 6a) and in neu-
rons of the dentate nucleus (Figure 6c). Markedly less in-
tense staining was occasionally seen in cerebral cortical
and hippocampal pyramidal neurons (not shown).
Figure 5 Immunostainings of Sw2 patient’s cerebellum (a, c, d resp. e, f, h, i represent semiconsecutive sections). a-c: C-terminal and
mid-domain antibodies abAβx-42, abAβx-40 and abAβ17–24 disclose similar pattern. There is abundant deposition in the Purkinje cell layer, from
where Aβ deposits extend as streaks towards the surface often loosely following penetrating arteries with distinct CAA. d-i: The more N-terminal
(beyond aa 17) abAβ8–17 (d); abAβ5–10 (e); and abAβ1–5 (f), as well as the specific abAβarc (g) render markedly weaker staining of the
parenchymal deposits, which is also weaker than with the pyroglutamate specific abAβ3pE (h) and abAβ11pE (i). With all Aβ antibodies blood
vessels stain approximately as strongly. (bar in a 500 μm for all panels).
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General alterations
In all Arctic AD patients’ brains neurons could be
frequently identified within the cortical plaques. Inter-
estingly, many of these neurons displayed relatively
minor degenerative changes with characteristic ves-
icular nuclei and prominent nucleoli but had often
somewhat condensed cytoplasm (Figure 7a). These neu-
rons were similar as those found within the large cotton
wool plaques in PS1Δ9 AD patients (Figure 7b). More-
over, confocal microscopy analysis of cortical sec-
tions double-labelled for Aβ and neurofilament showedthat some NF-positive axons traverse the plaques
(Figure 7c-d). Similarly, Purkinje cells surrounded by
abundant Aβ did not appear degenerating, not even
those with intracellular abAβ17–24 positive deposits
(Figure 6a-b).
Tau immunohistochemistry
Hp-tau immunopositivity was abundant in cerebral cortices
and it was mainly present as NTs. The frequency of NTs
was accentuated within the Aβ plaques and thus plaques
were delineated also by hp-tau staining (Figure 8a-g,
Additional file 2: Figure S7a and c). Similar accentuation
Figure 6 Higher magnifications of the Purkinje cell layer from patients Am1 (a) and Sw2 (b) show the abundant Aβ deposition.
Granular cytoplasmic staining is observed with abAβ17–24 (most likely AβPP) in a Purkinje cell (a), whereas with abAβx-42 (b) the cytoplasm is
negative. Cytoplasmic abAβ17–24 positivity is also seen in Sw2 patient’s cerebellar dentate neurons (c). (bar in a 30 μm; bar in b 50 μm;
bar in c 15 μm).
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plaques (Additional file 1: Figure S9i and j). NTs were usu-
ally abundant in cortical layers 2 and 3, markedly lesser in
layer 4, scarce to absent in layer 5, and slightly accentuated
in layer 6. Thus, the frequency of NTs by and large
corresponded to that of compact Aβ plaques (Figure 8a-c;
Additional file 2: Figure S7a and c). In calcarine cortex,
the abundance of NTs corresponded to Braak stage
VI, according to the BrainNet Europe recommenda-
tion (Additional file 2: Figure S7a). Within Aβ plaques
NTs were usually delicate, but occasionally they appeared
thicker approaching the appearance of DNs (Figure 8b
and g).
Variable numbers of neurons with hp-tau positive
NFTs were detected in all cerebral cortical areas examined
(Figure 8a, d-e). Neurofibrillary deposits were found in the
cytoplasm of small or atrophic neurons (Figure 8a, d-e),
whereas larger (non-degenerated) neurons in cortical layers
3, 5 and 6, including those located within Aβ plaques, were
usually devoid of NFTs (Figure 8b-c). Most commonly
neurons with NFTs were not distributed within though
nearby plaques (Figure 8d).Figure 7 Neurons and axons within neocortical Arctic Aβ plaques. a a
demonstrate occurrence of intact looking neuronal perikarya within a plaq
cotton wool plaque in a PS1Δ9 AD patient’s brain (b). c: Representative co
section from Sw2 patient’s temporal cortex displays numerous seemingly h
penetrating an abAβ17–24 positive Aβ deposit (green). d: A 50μm 3D projec
displays preserved axons within the Aβ deposits. (bar in a and b 40 μm; baMany hippocampal pyramidal neurons from CA4 to
subiculum as well as in adjoining entorhinal, transen-
torhinal and occipito-temporal cortices harboured promin-
ent NFTs (Figure 8f). Furthermore, many of the granule
cells in the dentate gyrus contained distinct hp-tau positive
inclusions (Figure 8g). In general, NTs were abundant in
the hippocampal neuropil and DNs were more prominent
within hippocampal than cortical Aβ plaques (Figure 8g).
In claustrum, the pattern of NTs, DNs and neurons with
NFTs was − like that of Aβ plaques − similar as in neocor-
tex (cf. Figure 8a-b and d). In thalamus, where the Aβ
plaques were small and diffuse, only few NFTs and very
delicate NTs were discernible. In putamen, where plaques
were even less conspicuous, almost no NTs were present
(not shown). In globus pallidus, where no Aβ deposits were
detected, neither were hp-tau immunoreactive structures
seen (not shown).
Despite the abundance of Aβ deposits in cerebellar
cortex and around Purkinje cells, no neurons (Purkinje
cells, granule cells or other neurons) harboured NFTs.
In addition, the number of NTs or DNs associated with
Aβ deposits was insignificant (not shown).nd b: Sections of frontal cortex immunostained with the abAβx-42
ue (arrows) in Sw2 patient’s brain (a; see also Figure 8c) and within a
nfocal z-scan (monolayer; x–y; x–z and y–z projections) of a 50μm
ealthy neurofilament (NF) positive axonal structures (red) within and
tion of the region indicated by an open arrow in Figure 7c, also
r in c 40 μm for c and d).
Figure 8 Tau pathology in Sw2 patient’s frontal (a-c and e) and temporal (d) cortex. a: Immunostaining for tau demonstrates abundant
NTs, most prominent within Aβ plaques in layers 2 and 3, less numerous in layers 1, 4 and 6 and scarce in layer 5. Scattered small/atrophic
neurons with NFTs are seen as dark spots (arrowheads). b and c: Consecutive sections demonstrate the accentuation of NTs within Aβx-42
positive plaques. A single plaque contains coarse DNs (arrow). The neuron within the large plaque (arrowhead) does not harbour a NFT.
d: Neurons with NFTs (arrowheads) are predominantly located outside plaques. e: A neuron with an NFT (black arrowhead) is located outside the
neighbouring plaque (asterisk) next to an hp-tau-negative neuron. f: Pyramidal neurons in CA1 of Sw1 patient’s hippocampus harbour prominent
NFTs (arrowheads). Abundant NTs and a seemingly intact neuron (arrow) are noticeable in the surrounding tissue. g: Small granule cells in Sw2
patient’s dentate gyrus contain hp-tau-positive inclusions (arrowheads). Copious NTs and some coarser DNs (arrows) are seen in the adjoining
hippocampal hilus. (bar in a 500 μm; bar in b 100 μm for b-d; bar in e 50 μm for e-g).
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In all four brains, there was slight to moderate reactive
astrogliosis in cerebral cortices. GFAP immunopositivity
was accentuated within the Aβ-immmunoreactive plaques
(Figure 9a-b), mainly as a meshwork of thin processes.Figure 9 Consecutive sections from Sw2 patient’s frontal cortex. GFAP
and it appears to be due to denser network of processes, since astrocyte c
outside the plaques (asterisks). c: The Aβ deposition induces only slight and
closely associate with the Aβ deposits in (b). (bar in a 200 μm for all panelAlthough the number of astrocytic cell bodies in cerebral
cortices appeared to be slightly increased, they were rela-
tively diffusely distributed instead of being strictly oriented
within or around plaques (Figure 9a-b). Microglial reac-
tion, as determined by Iba1 staining, in cerebral corticespositivity (a) is accentuated within the Aβx-40- positive plaques (b)
ell bodies (four marked with an arrow) are mainly located around or
diffuse microglial (Iba1-positive) reaction, which does not seem to
s).
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cells did not appear to follow the distribution of plaques
(Figure 9b-c). However, their frequency seemed to vaguely
correspond to the overall density of the NT meshwork
(not shown).
In cerebellum there was pronounced GFAP staining
around Purkinje cells (Bergmann astrocytes), although
not as prominent as for Aβ. In the molecular layer GFAP
positivity did not follow the perivascular streaks of Aβ de-
posits. Instead, loose GFAP-immunopositive astrocytic net-
work of varying intensity was found throughout the
molecular layer (Additional file 10: Figure S8a-b). In all pa-
tients, the Iba-1 immunoreactivity in cerebellum was weak
and diffuse compared to the Aβ deposition and astroglial
reaction and it did not specifically associate with Aβ de-
posits (Additional file 10: Figure S8c).
Vascular pathology
No major atherosclerosis in the circle of Willis was
present, neither were there infarcts, haemorrhages nor
microbleeds.
In all four patients’ brains leptomeningeal and cortical
penetrating arteries of widely different calibres were vari-
ably immunopositive with the different Aβ antibodies
used (e.g. Figures 2d and g, 5a-i and Additional file 9:
Figure S6a-i). In addition, capillaries in many particular
anatomic locations were positive for Aβ, most com-
monly with abAβx-40 (Figure 2d and Additional file 2:
Figure S7c). Presence of fibrillar Aβ within the vessel
walls, i.e. evidence of true cerebral amyloid angiopathy
(CAA), was verified by Congo positivity with green bi-
refringence in arteries, but not in capillaries (Figure 1d,
inset). Details of the composition, distribution and se-
verity as well as illustrations of CAA in these Arctic AD
patients’ brains will be presented in a separate article (in
preparation).
Discussion
Fulfilling the neuropathological criteria of AD
We performed neuropathological examinations of the
brains from four patients who carried the Arctic AβPP
mutation and whose clinical picture complies with AD.
We could demonstrate that the neuropathological hall-
marks of AD, Aβ plaques and deposition of hp-tau, were
prominent features in all four patients’ brains. However,
the Arctic AD pathology has certain features that deviate
from the common AD pathology [22], as it is referred to
in both of the latest consensus criteria [23-25].
When the ABC system of the new 2012 NIA-AA cri-
teria [23,25] is applied, the distribution of Aβ plaques, i.e.
NIA-AA component A = 3, since the accumulation of Aβ
is florid even in cerebellum (= Thal phase 5, [20]). As for
the neurofibrillary tau pathology (component B), the pres-
ence of NFTs throughout the neocortical regions fulfils thecriteria of Braak stage V-VI [26], i.e. NIA-AA component
B = 3. Braak stage V-VI is also met, if the Brain Net
Europe (BNE) staging is applied [27], as the neocortical
NTs are abundant in the striate area (occipital cortex;
Additional file 2: Figure S7a). The grading of component C
in the Arctic brains according to CERAD as recommended
in NIA-AA criteria is somewhat problematic, because of
the exceptional plaque structure. Although Aβ plaques are
compact, they are devoid of fibrillar amyloid cores and only
rarely harbour robust DNs. Nevertheless, we propose that
they do fulfil the CERAD criteria for neuritic plaques, since
they display delicate hp-tau positive NTs and occasional
DNs. The frequency of plaques should be considered fre-
quent, i.e. the component C = 3 [28].
Taken together, our neuropathological findings in the
Arctic AD patients’ brains meet both the 2012 NIA-AA
criteria for high level of AD- related changes (A3, B3,
C3) [23,25] and the previous NIA-RI criteria for a high
likelihood of AD [24]. The very rare α-synuclein positive
neurons encountered (not shown) most likely did not
contribute to the patients’ clinical picture. Neither did
we find any significant ischemic pathology, although
CAA was relatively prominent. Thus, the dementia caused
by the Arctic AβPP mutation is due to AD, albeit with
unique features of AD neuropathology.
Interestingly, the large, round cortical Arctic plaques
bear resemblance to the cotton wool plaques, such as
the Aβ deposits found in AD patients with PS1 muta-
tions [2-4]. Similarly, the cotton wool plaques and the
Arctic plaques are devoid of amyloid cores and harbour
very few hp-tau-positive DNs [3]. However, cotton wool
plaques have a homogeneous composition (Additional
file 1: Figure S9), whereas the Arctic plaques are com-
posed of variably truncated and spatially differentially
distributed Aβ and therefore when immunostained with
different Aβ antibodies they appear targetoid.
Amount of Aβ deposition
The extent of Aβ deposits in the Arctic AD patients’ brains
was massive, which may explain why the weights of Sw1,
Sw2 and Am2 brains were considerably higher than what
is commonly recorded in sporadic AD. Alzheimer brains
are usually atrophic, but no studies have systematically
compared the brain weight with the Aβ burden. Interest-
ingly, the brain weights in three of the five PS1Δ9 AD pa-
tients with large cotton wool plaques of similar abundance
as Aβ plaques in our Arctic AD patients’ brains were
within normal limits [3].
Hierarchical order of Aβ deposition
In sporadic AD, Aβ deposition has been suggested to
occur hierarchically in five phases [20]. The distribution
of Aβ deposits in the Arctic AD patients’ brains corre-
sponds to Thal’s most advanced phase 5, for which the
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Aβ deposits were highly abundant in all Arctic AD pa-
tients’ cerebellum, but they were few in brain stem nuclei–
the criterion for phase 4. These features suggest that, in
these brains, cerebellum may have become involved at an
earlier phase or at a faster pace than the brain stem.
Thus, the Arctic AβPP mutation may alter the hierarchy
according to which the Aβ deposits are generally seen to
emerge in AD patients’ brains. Perhaps abundant extra-
cellular perivascular Aβ aggregates in Arctic AD brain
overwhelm the perivascular drainage pathways [29] in
cerebellum leading to an early pathology. Moreover, the
pattern of Aβ deposition and distribution in our Arctic
patients’ cerebellum was exceptional (see next section).
Variation in the distribution of Aβ deposition
The pattern and composition of Aβ deposits in the Arc-
tic AD brain revealed additional topographic variability.
The ring plaques, originally discovered by Bielschowsky
silver and immunostaining with abAβx-42 [17], were −
with the use of additional Aβ antibodies − shown to be
targetoid rather than ring-shaped (as preliminarily dem-
onstrated in our previous article [18] and now in greater
detail in this article). These plaques were almost only
observed in cerebral cortex, whereas in other anatomical
locations the plaques were usually of more irregular and
diffuse types.
Interestingly, in claustrum the pattern of Aβ deposits
was similar to that in cerebral cortex. This is consistent
with a previous observation of cotton wool plaques in
PS1Δ9 AD patients’ brains [30]. In addition, the tau path-
ology in claustrum was similar as in cerebral cortex. Claus-
trum is generally considered to be a part of the basal
ganglia and the presence of plaques in this region would
thus correspond to Thal’s phase 3. However, this pattern
was strikingly different from that in the other subcortical
grey matter nuclei. For example, globus pallidus was virtu-
ally negative for Aβ plaques, while only small diffuse
plaques could be found in putamen, thalamus and caudate
nucleus. This discrepancy may be related to the fact that,
of these regions, only claustrum has bidirectional connec-
tions with almost all cortical regions [31].
The pattern of cerebellar Aβ deposits differed remark-
ably from the commonly observed restriction of deposits
to the molecular layer in sporadic AD [20] and from the
abundance of cored plaques in PS1Δ9 AD patients’ cere-
bellum. In the Arctic AD patients’ brains, the abundant
Aβ deposition next to the Purkinje cells may indicate ac-
tive Aβ production in these cells. Moreover, the apparent
pattern of Aβ deposition along the perivascular drainage
pathways (also depicted in NIA-AA article by Hyman
et al. 2012 [23]) may be explained by a relatively profuse
transport of extracellular Aβ through the molecular layer
to the subarachnoid space [29].Differential truncation of Aβ
The composition of Aβ deposits in both sporadic
and familial AD brains has been shown to be highly
variable, with both N- and C-terminal truncations and
modifications [32-37].
Our mass spectrometric analyses, in which we im-
munoprecipitated both wt and mutated Aβ from the
temporal cortex of the patient Sw2 with antibodies against
two distinct Aβ epitopes (ArcAβ17–24 and wtAβ17–24),
demonstrated that the deposits contained variably trun-
cated and modified Aβ species, both wt and Arctic Aβ.
Furthermore, our immunohistochemical stainings re-
vealed that although all four patients carried the same
AβPP mutation, both the distribution and the compos-
ition (truncations or modifications) of the Aβ deposits
showed considerable inter- and intra-individual variabil-
ity. This should not actually be surprising, since it is most
likely that the “machinery and milieu” in the AβPP pro-
duction, processing and/or Aβ aggregation are not identi-
cal in the four individual Arctic AD patients, nor in
different anatomic regions within each patient’s brain.
Whether a similar variability in the composition of Aβ
deposits exists in other forms of FAD has been the sub-
ject of several studies [5,34-37].
The variability in the composition of deposited Aβ also
sets new requirements for the antibodies used in diag-
nostic work. Since truncations can occur at many different
sites of the Aβ peptide, some antibodies give virtually nega-
tive parenchymal staining. Thus, either an antibody against
the mid-portion of Aβ preferably against an epitope located
C-terminally to aa 11 (to avoid problems with 11pE trun-
cated Aβ species) and N-terminally to aa 40 (to avoid prob-
lems with the different C-terminal truncations), or a
mixture of different antibodies should be recommended
for routine analyses. In our hands, the antibody abAβ17–24
(clone 4G8) appeared to best fulfil such requirements
(even though it also recognizes AβPP [21]), whereas the
other widely used mid-portion antibody abAβ8–17 (clone
6F/3D) yielded inconsistent results. For instance, it gave
only vague staining of the cerebellar parenchymal de-
posits, although it stained blood vessels in this region
clearly positively.
It is known that the Arctic mutation interferes with
the processing of AβPP by making it less prone for α-
secretase cleavage, while elevating β-secretase cleaved
fragments [12,38]. Natural processing of AβPP at the β′-
site (at Aβ aa 10/11) is also favoured over the β-site (at
Aβ aa −1/1) in situations when accession to it by BACE1
enzyme is affected, e.g. through structural twists in
AβPP [39]. Moreover, N-terminally truncated and modi-
fied Aβ peptides (e.g. AβpE3-x and AβpE11-x) have been
shown to be significantly increased in the brains of AD
patients with various PS1 mutations [36,40]. Our data
show that the Arctic mutation like the PS1 mutations
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since we observed 3pE40arc, 11pE40arc and 11pE42arc
in our MS measurements (Figure 3e, Additional file 5:
Table S1 and [18]), and considerable immunopositivities
with ab3pE and ab11pE antibodies. However, since we also
observed a heterogeneous population of N-terminally
truncated Aβ peptides, additional (primary/secondary)
cleavages are also likely to occur in the Arctic AD brain.
Aβ-peptides might also aggregate in a way that exposes
cleavage sites and facilitates peptide truncation and their
modifications as a secondary process.
Lack of fibrillar Aβ and amyloid cores is a character-
istic feature of both Arctic plaques and PS1Δ9 cotton
wool plaques. The reason for this feature in these two
genetic variants of AD is unknown. Certain properties
of the mutated forms of Aβ such as posttranslational
modifications and altered propensity to oligomerize/
aggregate, could offer an explanation for the limited for-
mation of structurally ordered Aβ fibrils in Arctic AD pa-
tients [41], whereas the underlying reason in the PS1Δ9
AD patients is even less clear, because the cotton wool
plaques in such brains contain wild-type Aβ only. It
might be that in these two types of FAD Aβ aggregation
is too rapid and does not lead to Congo-red positive, fi-
brillar Aβ deposits.
It has been shown that the Arctic mutation leads to an
accelerated oligomerization and disordered fibrillogenesis
of Aβ, measured both in vitro [11,41-44] and in vivo
[11,45,46]. The diameter of Arctic Aβ fibrils correlated
with decreased neuronal viability [42]. Recent in vitro ex-
periments on the aggregation process of ArcAβ1–40 [41]
demonstrated that at least four types of fibrils can be
identified. The intermediate phase of spherical aggregates
appeared at earlier time points and ArcAβ1–40 fibrils po-
lymerized more rapidly and at lower concentrations than
wt Aβ1–40 fibrils. At late stages fragmentation and clus-
tering of ArcAβ1–40, but not of wtAβ1–40, fibrils were ob-
served [41]. The results of these experiments are in
agreement with the suggestion that spherical aggregates
(containing abundant β-hairpin and/or β-sheet struc-
tures), and/or Aβ oligomers have a pathogenic role in the
AD brain. Especially the larger soluble oligomers, i.e.
protofibrils, are known to have neurotoxic properties.
However, an alternative Aβ aggregation pathway, differ-
ent from simple assembly of spherical aggregates and
protofilaments into fibrils, has also been proposed [41],
which may contribute to the distinct morphology of Aβ
plaques in Arctic AD patients (i.e. Congo-red negativity
of the Arctic AD deposits). Moreover, co-incubation of
ArcAβ with wtAβ1-40 led to kinetic stabilization of Arctic
protofibrils [47]. An increase in the ratio of ArcAβ to
wtAβ in Arctic AD may result in the rapid accumulation
of neurotoxic protofibrils and acceleration of the disease
process [48].Cellular pathologies
The large plaques in both the Arctic and PS1Δ9 AD pa-
tients’ brains were found to embrace neurons. More specif-
ically, in all four Arctic brains seemingly viable neocortical
pyramidal neurons and cerebellar Purkinje cells could be
identified within several plaques of variable Aβ compos-
ition. Interestingly, the perikarya of these neurons seemed
intact and did not appear to be under way to develop
neurofibrillary pathology. This sparing of neuronal peri-
karya is in accordance with the notion that intraneuronal
Aβ triggers neuron loss in AD [49]. In several animal
models it has been demonstrated that extracellular Aβ
plaques do not seem to instigate neuronal death, whereas
accumulation of intraneuronal Aβ correlated well with the
loss of neurons [50], including a transgenic model express-
ing pyroglutamate Aβ3pE-42 [51].
We showed that even apparently intact axons tra-
versed the plaques. These observations are phenomena,
similar to those in PS1Δ9 AD patients, i.e. axons are not
pushed aside to wind around the accumulated Aβ. How-
ever, the relatively low number of neurofilament positive
intraplaque axons may indicate that axons traversing
Arc plaques suffer from some degree of degeneration, as
it was interpreted to occur within PS1Δ9 AD patients’
cotton wool plaques [3]. The intraplaque accentuation of
NTs (i.e. axons containing hp-tau) in both Arc and
PS1Δ9 plaques supports the suspicion of axonal degen-
eration. Accumulation of pathogenic species of micro-
tubule associated tau protein can impair axoplasmic
transport and consequently contribute to synaptic loss,
which may be pivotal in the pathogenesis of AD [52]. If
the synaptic contacts are lost, sparing of the perikarya or
axons en route cannot prevent functional loss (and fur-
ther degeneration). The fate of axons within Aβ plaques
obviously merits further analysis.
Furthermore, the non-fibrillar type of Aβ deposits in
the Arctic brain induced only a limited reactive re-
sponse. Although the density of astrocytic processes was
increased within the Arctic Aβ deposits (clearly visible
around Purkinje cells), the astrocytic cell bodies appeared
not to cluster around the non-fibrillar Aβ deposits. Like-
wise, in PS1Δ9 AD patients’ brains astrocytes did not
cluster around the non-fibrillar cotton wool plaques, al-
though in these brains the scarce cored plaques were
surrounded by an increased number of astrocytes [3].
Similarly, the Arctic non-fibrillar plaques did not appear
to attract microglial cells. The presence of preserved
neuronal perikarya and axons as well as the lack of acti-
vated glial cells strengthen the perception of extracellular
non-fibrillar Aβ deposits as being relatively non-toxic.
Thus, it is conceivable that Aβ oligomers, which are con-
sidered pathogenic, exert their effects already within the
neurons or by being diffusely distributed (not in plaques)
in the parenchyma.
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We have demonstrated special neuropathologic character-
istics in the brains of four deceased AD patients with the
Arctic AβPP mutation (p.E693G/p.E22G). The amount of
Aβ deposited in the brains was profuse, but virtually all
parenchymal deposits were composed of non-fibrillar,
Congo negative Aβ aggregates Aβ Congo red only
stained the walls of moderately to severely angiopathic
vessels. Mass spectrometric analyses on temporal cor-
tex samples showed that the Aβ deposits contained
variably truncated and modified wt and mutated ArcAβ
species. The structure and composition of the Aβ de-
posits varied considerably between the patients. In
three of the four analysed Arctic AD brains, the plaque
centres containing C-terminally (beyond aa 40) and
variably N-terminally truncated Aβ were surrounded
by Aβx-42 immunopositive coronas giving the plaques a
targetoid appearance. Furthermore, in each individual
the architectural pattern of plaques was found to vary
between different anatomic regions–from diffuse de-
posits to targetoid or ring-shaped plaques. Tau pathology
appeared mainly as delicate neuropil threads with accentu-
ation within Aβ plaques. Thicker dystrophic neurites were
only occasionally observed. Neurons within the large Aβ
plaques appeared relatively intact. Thus, the extracellular
deposits of non-fibrillar Aβ did not seem to directly dam-
age neuronal perikarya or to induce formation of neurofib-
rillary tangles, supporting the present view of intracellular
Aβ oligomers being neurotoxic. The enrichment of NTs
within plaques may indicate axonal damage, even though
neurofilament positive axons traversing plaques were
detected. Finally, similarly as the cotton wool plaques in
PS1Δ9 AD, the Arctic plaques induced only a modest glial
and inflammatory tissue reaction.Availability of supporting data
The supplemental figures (named as Additional files 1, 2,
3, 4 and 6, 7, 8, 9, 10) and supplemental table (named as
Additional file 5) supporting the results of this article are
included within the article.Additional files
Additional file 1: Figure S9. Immunostainings of semiconsecutive
sections from a PS1Δ9 AD patient’s frontal (ah) and temporal (i and j)
cortex. The cotton wool plaques are similarly rounded structures as Arctic
plaques, but the different antibodies stain them homogeneously, although
with different intensities. The strong staining with abAβx-42 (a) suggests that
majority of Aβ terminates at aa 42, whereas Aβx-40 (b) species are scarce.
N-termini appear to be markedly variable including considerable amounts
of N-terminally truncated Aβ species starting with pyroglutamate (Aβ11pE or
Aβ3pE; g and h). The homogeneous staining suggests that the variably
truncated Aβ species are relatively evenly distributed within the plaques.
i and j: Sections from temporal cortex show accumulation of hp-tau
positive NTs within Aβ plaques (six plaques marked with numbers). Notethe NTs (arrows) also in the subpial Aβ positive edging (asterisks) (bar in a
100 μm for a-h; bar in i 150 μm for i and j).
Additional file 2: Figure S7. a: Sw2 patient’s striate area (visual cortex).
The marked density of hp-tau positive NTs, including moderate density in
layer 5, qualifies for the Braak stage VI of BrainNet Europe recommendation.
The distribution of NTs by and large corresponds to that of Aβ plaques in the
consecutive section c (asterisks). Note also the numerous Aβ-positive
capillaries in layers 4–5. LFB-CV = Luxol fast blue-cresyl violet. (See also
Figure 2d) (bar in a 400 μm for all panels).
Additional file 3: Figure S1. In semiconsecutive sections from Am1
patient’s frontal cortex the plaques appear ring-shaped with C-terminal
abAβx-42 and abAβx-40, mid-domain abAβ17-24 and Arctic specific abAβarc
(a-c and g plus insets), whereas with more N-terminal (beyond aa 17)
abAβ8-17, abAβ5-10 and abAβ1-5 (d-f) the plaques stain progressively
weaker, although some plaques have intensely stained centres. Robust
staining with abAβarc suggests an abundance of Arctic Aβ and a fair
amount of Aβ appears to have pyroglutamate at positions 3 and 11 (h and i).
The lesser number of plaques in layer 4 creates a sparsely populated band,
best visible in b-d and g-i (similar band was observed in Am2 patient). No
plaques are detectable in layer 1. Leptomeningeal blood vessels in b-i are
strongly Aβ-positive, whereas in a they are only weakly positive. (bar in a
300 μm for all panels).
Additional file 4: Figure S2. Semiconsecutive sections from Sw1
patient’s frontal cortex. All antibodies except for abAβ1-5 disclose ring-
shaped plaques (insets and arrows) in layers 2–6. The small subpial
plaques in layer 1 are of diffuse type. Contrary to findings in patients Sw2
(Figure 4) and Am1 (Additional file 3: Figure S1) plaque centres are not
intensely stained (bar in a 300 μm for all panels).
Additional file 5: Table S1. Aβ peptides detected in MALDI-TOF analyzes
of immunoprecipitates from temporal cortex of Arctic AD Sw2 patient brain.
Legend: Aβ peptides were measured in positive linear mode on AutoflexIII
imager Bruker MALDI-TOF spectrometer in two independent experiments
(named as exp1 and exp2). All m/z listed represent [Mav+H]+ (± 3 Da), after
smoothing and background subtraction. Extraction of Aβ peptides was
performed in 99% formic acid. Immunoprecipitation (IP) was performed with
abAβ17-24 (Mab4G8) and abAβarc (Mab27) antibodies. Asterisks mark peaks
labeled in Figure 3e. Molecular weight (m/z) in Daltons (Da). Relative
intensities of the peaks in relation to the most intensive peak (Aβ17-43wt)
were calculated with FlexAnalysis 3.4 software (Bruker Daltonics). The data
from experiment 1 were presented in Philipson et al. Neurobiol Aging (2012),
33: 1010 e1011-1013 [18].
Additional file 6: Figure S3. Sw2 patient’s hippocampus. a: In H&E
stained sections the plaques are difficult to discern, except when they are
located within the dentate gyrus displacing granule cells (arrows). b: With
Bielschowsky silver impregnation DNs within plaques are clearly visible,
whereas plaques themselves are inconspicuous. Inset: NFT in a hippocampal
pyramidal neuron is strongly silver positive. (bar in a 100 μm for a and b).
Additional file 7: Figure S4. a-g: Aβ-plaques in Swe2 patient’s
claustrum show similar targetoid pattern as in neocortex (a-c consecutive
sections). a: With abAβx-42 dark corona and pale centre. b: With abAβx-40
fair staining of both centre and corona. c: With abAβ1-5 dark centre and
pale corona. d: Middomain abAβ17-24 stains strongly both centre and
corona. e: Specific abAβarc. gives similar pattern as abAβ17-24, though with
much lesser intensity. f and g: Plaques comprise of both Aβ3pE and
Aβ11pE, though less of the latter. h-k: Plaques in Sw2 patient’s putamen
are small and diffusely stained. The most intense stainings are seen with
abAβx-42, abAβarc and abAβ3pE (h, j and k) suggesting an abundance of
Aβ with pyroglutamate-modified N-termini, which is consistent with the
virtually negative abAβ1-5 staining (i). l: In Sw2 patient’s amygdala plaques
are similar as in putamen but more numerous. m: In Sw2 patient’s
thalamus the plaques are ragged and weakly stained. (bar in a 100 μm
for a-c; bar in d 100 μm for d-g; bar in h 50 μm for h-l; bar in m 50 μm).
Additional file 8: Figure S5. a-k: Sw2 patient’s medulla. A few compact
plaques are positive with C-terminal (a), mid-domain (b) and N-terminal
antibodies (c). Remarkably, abAβx-42 renders the neuropil in inferior
olivary nucleus distinctly positive (a and d), whereas with the other
antibodies it is negative (b, c and e-i). Both abAβx-42 and abAβ17-24,
(d and e; arrows), but not the rest of Aβ antibodies applied (f-i), stain
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neurons within and adjacent to plaques. The neuronal inclusions also
stain with PAS (j) and an antibody to lysosomal cathepsin D (k). (bar in a
350 μm for a-c; bar in d 50 μm for d-i; bar in j 25 μm; bar in k 30 μm).
Additional file 9: Figure S6. a-i: Immunostainings of Am1 patient’s
cerebellum demonstrates the marked interindividual variation despite the
same genetic defect (cf. Figure 5). Only abAβx-42 and abAβ17-24 are clearly
positive (a and c), whereas abAβx-40 (b) and the more N-terminal abAβ8-17,
abAβ5-10 and abAβ1-5 (d-f) give virtually no parenchymal staining, even
though the blood vessels are strongly positive. Weak staining with
abAβarc (g) is consistent with most parenchymal deposits being composed of
wild-type Aβ. A fair proportion of the deposited Aβ appears to have
pyroglutamate N-termini (h and i). (bar in a 150 μm for all panels).
Additional file 10: Figure S8. Sw2 patient’s cerebellum. a: The density
of GFAP-positive network is prominent, especially in the molecular layer.
b: The density of the network corresponds to the deposition of Aβ in the
Purkinje cell layer, but it differs from the perivascular accentuation of Aβ
in the molecular layer. c: The microglial reaction to Aβ is minimal (bar in
a 200 μm for all panels).
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